Wells Fargo downgraded Glaukos (GKOS) to Equal Weight from Overweight with a price target of $86, down from $160. The growth runway for iDose is priced into the shares while the base business offers no upside, the analyst tells investors in a research note. Wells says its sum-of-the-parts analysis indicates Glaukos’ iDose growth runway is priced in at current share levels. Meanwhile, the company’s base business is expected to grow flat year-over-year in fiscal 2025, contends the firm.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos downgraded to Equal Weight from Overweight at Wells Fargo
- Positive Buy Rating for Glaukos Amid Strong iDose Performance and Awaited FDA Decision
- Glaukos’s Promising Outlook: Buy Rating Amid Strong Sales and Strategic Growth Opportunities
- Glaukos Corp. Reports Strong Q1 2025 Growth
- Closing Bell Movers: Microsoft and Meta rally after earnings
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue